Cyclerion Therapeutics, Inc.·4

Jul 26, 4:33 PM ET

Hyman Steven 4

4 · Cyclerion Therapeutics, Inc. · Filed Jul 26, 2022

Insider Transaction Report

Form 4
Period: 2022-07-25
Hyman Steven
Director
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-07-25+57,75357,753 total
    Exercise: $0.78Exp: 2032-07-25Common Stock (57,753 underlying)
Footnotes (1)
  • [F1]The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

Documents

1 file
  • 4
    form4.xmlPrimary

    FORM 4